Bigeminy and Fatigue: Clinical Presentation and Management

Mechanisms and Clinical Presentation

Bigeminy creates an apical-radial pulse deficit where premature beats fail to generate sufficient stroke volume to produce a palpable peripheral pulse, effectively reducing cardiac output by up to 50% 1, 2.
The repetitive pattern of normal beats followed by premature beats results in ineffective cardiac contractions that don't contribute meaningfully to tissue perfusion, leading to symptoms of reduced cardiac output including fatigue 1.
Patients may present with effective bradycardia despite a normal underlying sinus rate, as the premature beats don't generate adequate forward flow 2.
The hemodynamic consequences manifest as symptoms consistent with low cardiac output states, which prominently include fatigue and exercise intolerance 1, 2.

24-48 hour Holter monitoring quantifies the burden of premature beats and determines whether bigeminy is persistent or intermittent 1, 2.
Extended monitoring beyond 24 hours should be considered for patients with intermittent symptoms like fatigue or lightheadedness 2.
Exercise stress testing determines if bigeminy is exacerbated or suppressed with exercise, which helps explain exercise-related fatigue 2.
For symptomatic patients, beta-blockers are first-line therapy, especially when associated with heightened adrenergic tone 2.
In patients with structural heart disease and persistent symptoms despite beta-blockers, amiodarone should be considered 2.
The American College of Cardiology and European Heart Journal guidelines recommend avoiding the routine use of prophylactic antiarrhythmic drugs for suppression of isolated ventricular premature beats in asymptomatic patients with structural heart disease 2.

QTc >500 ms with bigeminy indicates extremely high risk for torsades de pointes and warrants immediate intervention 1.
Bigeminy in the setting of acute myocardial infarction indicates ongoing electrical instability 1.
In catecholaminergic polymorphic ventricular tachycardia (CPVT), exercise-induced premature ventricular contractions in bigeminy represent a high-risk pattern 3.
Pacemaker implantation should be considered for bigeminy associated with significant conduction system disease causing symptomatic bradycardia 2.
ICD implantation is appropriate if bigeminy is associated with high-risk features for sudden cardiac death, particularly in patients with structural heart disease 2.

The American College of Cardiology recommends repeat Holter monitoring every 1-2 years to monitor for progression or development of more malignant arrhythmias in asymptomatic patients without structural heart disease 4
For patients with bigeminy, management should follow STEMI or NSTE-ACS guidelines, prioritizing revascularization and standard ACS therapies, according to the European Heart Journal, Circulation, and Journal of the American College of Cardiology 5, 6, 7

Extended monitoring (>24 hours) or event recording is recommended to capture and correlate symptoms with rhythm, as suggested by the Journal of the American College of Cardiology 4